Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Go Makimoto; Katsuyuki Hotta; Katsuyuki Kiura

doi:10.1016/j.resinv.2019.03.004

Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Go Makimoto, Katsuyuki Hotta, Katsuyuki Kiura

University Hospital

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

Original language	English
Pages (from-to)	330-336
Number of pages	7
Journal	Respiratory Investigation
Volume	57
Issue number	4
DOIs	https://doi.org/10.1016/j.resinv.2019.03.004
Publication status	Published - Jul 2019

Keywords

Chemoradiotherapy
Durvalumab
Immune checkpoint inhibitor
Lung cancer
Stage III

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.resinv.2019.03.004

Cite this

@article{84809d9adba947d5b4a898054404a913,

title = "Recent trends in the treatment of unresectable stage III non-small-cell lung cancer",

abstract = "Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.",

keywords = "Chemoradiotherapy, Durvalumab, Immune checkpoint inhibitor, Lung cancer, Stage III",

author = "Go Makimoto and Katsuyuki Hotta and Katsuyuki Kiura",

note = "Funding Information: Go Makimoto declares no conflicts of interest. Katsuyuki Hotta received honoraria from Astrazeneca and MSD, and research funding from Chugai pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and Astellas Pharma. Katsuyuki Kiura received honoraria from Astrazeneca and Eli Lilly Japan, research funding from Boehringer Ingelheim, Ono pharmaceutical, and Pfizer, and donations from Chugai pharmaceutical, Taiho pharmaceutical, Ono pharmaceutical, Nippon Kayaku, and Boehringer Ingelheim. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = jul,

doi = "10.1016/j.resinv.2019.03.004",

language = "English",

volume = "57",

pages = "330--336",

journal = "Respiratory Investigation",

issn = "2212-5345",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

AU - Makimoto, Go

AU - Hotta, Katsuyuki

AU - Kiura, Katsuyuki

N1 - Funding Information: Go Makimoto declares no conflicts of interest. Katsuyuki Hotta received honoraria from Astrazeneca and MSD, and research funding from Chugai pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and Astellas Pharma. Katsuyuki Kiura received honoraria from Astrazeneca and Eli Lilly Japan, research funding from Boehringer Ingelheim, Ono pharmaceutical, and Pfizer, and donations from Chugai pharmaceutical, Taiho pharmaceutical, Ono pharmaceutical, Nippon Kayaku, and Boehringer Ingelheim. Publisher Copyright: © 2019

PY - 2019/7

Y1 - 2019/7

N2 - Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

AB - Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

KW - Chemoradiotherapy

KW - Durvalumab

KW - Immune checkpoint inhibitor

KW - Lung cancer

KW - Stage III

UR - http://www.scopus.com/inward/record.url?scp=85064154380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064154380&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2019.03.004

DO - 10.1016/j.resinv.2019.03.004

M3 - Review article

C2 - 31000495

AN - SCOPUS:85064154380

SN - 2212-5345

VL - 57

SP - 330

EP - 336

JO - Respiratory Investigation

JF - Respiratory Investigation

IS - 4

ER -

Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this